Non Alcoholic Fatty Liver Clinical Trial
Official title:
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study
This Study purpose to verify change of variety factors that the cause of nonalcoholic fatty liver disease and its process through salsalate injection to osteoarthritis patient who has non alcoholic fatty liver
Salsalate, the salicylic acid dimer that is one of anti-inflammatory and kind of salicylate.
Aspirin(Acetylated salicylic) is known as nonsteroidal anti-inflammatory, also salsalate is
widely used painkiller and anti-inflammatory without prescription in Europe and America
through the long time and it was approved as osteoarthritis and rheumarthritis treatment in
Korea. Especially salsalate is switched to salicylic acid(active metabolite) 15% rate lower
than the same dose of aspirin (3.5g vs. 5g).
Salsalate is cyclooxygenase antagonist, it make anti-inflammatory effect by hinder creation
of variety inflammatory induction factors like interleukin-6, Tumor Necrosis Factor
(TNF)-alpha, C-reactive protein. This anti-inflammatory reaction is known to block Nuclear
Factor(NF)-kappaB gene action by hinder action of IkappaB kinase. Also salsalate was reported
it has positive effect to gluco metabolism as performed role of insulin-sensitizing.
Therefore, the above mechanism of salsalate was expected that it can be had positive effect
to metabolic disease like diabetes and obesity, and related studies are performed
considerably at present.
There is no clinical trial for non alcoholic fatty acid related salsalate, and there was the
animal study result that salsalate may reduce occurence of non alcoholic fatty acid and
fibrosis by hinder non alcoholic fatty acid creation and inflammation mediation path.
Therefore, this Study purpose to verify change of variety factors that the cause of
nonalcoholic fatty liver disease and its process through salsalate injection to
osteoarthritis patient who has non alcoholic fatty liver
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03625284 -
Oral Dietary Fucoxanthin Rich Supplement for Liver Health
|
N/A | |
| Completed |
NCT02923804 -
Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients
|
N/A | |
| Completed |
NCT04823676 -
Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management
|
N/A | |
| Completed |
NCT03186859 -
Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)
|
N/A | |
| Completed |
NCT02030977 -
The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06176079 -
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
|
||
| Not yet recruiting |
NCT06138821 -
ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial
|
Phase 4 | |
| Not yet recruiting |
NCT04553796 -
Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
|
||
| Not yet recruiting |
NCT03801577 -
Hepaxa Management of Non-alcoholic Fatty Liver Disease
|
N/A | |
| Completed |
NCT05804422 -
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study)
|
N/A | |
| Recruiting |
NCT04625166 -
Combi-elastography Assessment of Chronic Liver Disease Multi-center Study
|
||
| Recruiting |
NCT05523024 -
Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.
|
N/A | |
| Not yet recruiting |
NCT05822622 -
Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.
|